SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role

Din, Ahmad Ud; Mazhar, Maryam; Waseem, Muhammad; Ahmad, Waqar; Bibi, Asma; Hassan, Adil; Ali, Niaz; Wang, Gang; Gao, Qian; Ullah, Razi; Shah, Tariq; Ullah, Mehraj; Khan, Israr; Nisar, Muhammad; Wu, Jianbo

doi:10.1016/j.biopha.2020.110947

Cited by 86 publications

(78 citation statements)

References 165 publications

(181 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As an important component of human immunity and metabolism, gut microbes have attracted extensive attention in COVID-19 19 – 23 . In a pilot study of 15 patients with COVID-19, Zuo et al 20 found persistent alterations in the faecal microbiome during hospitalization compared with controls, and these alterations were associated with faecal levels of SARS-CoV-2 and COVID-19 severity.…”

Section: Discussionmentioning

confidence: 99%

Gut mycobiota alterations in patients with COVID-19 and H1N1 infections and their associations with clinical features

Jiang

et al. 2021

Commun Biol

View full text Add to dashboard Cite

The relationship between gut microbes and COVID-19 or H1N1 infections is not fully understood. Here, we compared the gut mycobiota of 67 COVID-19 patients, 35 H1N1-infected patients and 48 healthy controls (HCs) using internal transcribed spacer (ITS) 3-ITS4 sequencing and analysed their associations with clinical features and the bacterial microbiota. Compared to HCs, the fungal burden was higher. Fungal mycobiota dysbiosis in both COVID-19 and H1N1-infected patients was mainly characterized by the depletion of fungi such as Aspergillus and Penicillium, but several fungi, including Candida glabrata, were enriched in H1N1-infected patients. The gut mycobiota profiles in COVID-19 patients with mild and severe symptoms were similar. Hospitalization had no apparent additional effects. In COVID-19 patients, Mucoromycota was positively correlated with Fusicatenibacter, Aspergillus niger was positively correlated with diarrhoea, and Penicillium citrinum was negatively correlated with C-reactive protein (CRP). In H1N1-infected patients, Aspergillus penicilloides was positively correlated with Lachnospiraceae members, Aspergillus was positively correlated with CRP, and Mucoromycota was negatively correlated with procalcitonin. Therefore, gut mycobiota dysbiosis occurs in both COVID-19 patients and H1N1-infected patients and does not improve until the patients are discharged and no longer require medical attention.

show abstract

Section: Discussionmentioning

confidence: 99%

Gut mycobiota alterations in patients with COVID-19 and H1N1 infections and their associations with clinical features

Jiang

et al. 2021

Commun Biol

View full text Add to dashboard Cite

show abstract

“…Probiotics stimulate the secretion of IgG and IL-10 from the activated T-cells. It is essential to use probiotics along with prebiotics for the treatment of COVID-19 individuals ( Din et al., 2021 ). Bacteriocin compounds such as staphylococcin 188, enterocin AAR-74, erwiniocin NA4 showed antiviral activity against HIV, HSV, Coliphage, influenza virus, and H1N1 virus ( Gohil et al., 2021 ).…”

Section: Gut Microbiome In the Elderly Covidants: Does It Explain Higmentioning

confidence: 99%

SARS-CoV-2-Indigenous Microbiota Nexus: Does Gut Microbiota Contribute to Inflammation and Disease Severity in COVID-19?

Chattopadhyay

Shankar

2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Gut microbiome alterations may play a paramount role in determining the clinical outcome of clinical COVID-19 with underlying comorbid conditions like T2D, cardiovascular disorders, obesity, etc. Research is warranted to manipulate the profile of gut microbiota in COVID-19 by employing combinatorial approaches such as the use of prebiotics, probiotics and symbiotics. Prediction of gut microbiome alterations in SARS-CoV-2 infection may likely permit the development of effective therapeutic strategies. Novel and targeted interventions by manipulating gut microbiota indeed represent a promising therapeutic approach against COVID-19 immunopathogenesis and associated co-morbidities. The impact of SARS-CoV-2 on host innate immune responses associated with gut microbiome profiling is likely to contribute to the development of key strategies for application and has seldom been attempted, especially in the context of symptomatic as well as asymptomatic COVID-19 disease.

show abstract

“…This effect persisted even after nasopharyngeal clearance of SARS-CoV-2[ 46 ]. Other factors could also play a role in inducing dysbiosis in patients with COVID-19, including the presence of other comorbidities that negatively affect the gut microbiota, such as diabetes mellitus, hypertension, and old age; the use of antibiotics, antivirals, antifungals, and steroids; and other intensive care units milia that could negatively affect and alter the gut microbiome[ 47 ].…”

Section: Implications Of Gastrointestinal Infection In Covid-19mentioning

confidence: 99%

Paediatric gastrointestinal disorders in SARS-CoV-2 infection: Epidemiological and clinical implications

Al‐Biltagi¹,

Saeed²,

Bediwy³

et al. 2021

WJG

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic is a threat worldwide for individuals of all ages, including children. Gastrointestinal manifestations could be the initial presenting manifestation in many patients, especially in children. These symptoms are more common in patients with severe disease than in patients with non-severe disease. Approximately 48.1% of patients had a stool sample that was positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA. Children typically form 1%-8% of all laboratory-confirmed cases of SARS-CoV-2. Gastrointestinal manifestations of COVID-19 in children are not rare, with a prevalence between 0 and 88%, and a wide variety of presentations, including diarrhoea, vomiting, and abdominal pain, can develop before, with or after the development of respiratory symptoms. Atypical manifestations such as appendicitis or liver injury could also appear, especially in the presence of multisystem inflammatory disease. In this review, we discussed the epidemiology of COVID-19 gastrointestinal diseases in children as well as their implications on the diagnosis, misdiagnosis, prognosis, and faecal-oral transmission route of COVID-19 and the impact of gastrointestinal diseases on the gut microbiome, child nutrition, and disease management.

show abstract

SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role

Cited by 86 publications

References 165 publications

Gut mycobiota alterations in patients with COVID-19 and H1N1 infections and their associations with clinical features

Gut mycobiota alterations in patients with COVID-19 and H1N1 infections and their associations with clinical features

SARS-CoV-2-Indigenous Microbiota Nexus: Does Gut Microbiota Contribute to Inflammation and Disease Severity in COVID-19?

Paediatric gastrointestinal disorders in SARS-CoV-2 infection: Epidemiological and clinical implications

Contact Info

Product

Resources

About